TriSalus Life Sciences (TLSI) Total Non-Current Liabilities (2022 - 2026)

TriSalus Life Sciences has reported Total Non-Current Liabilities for 5 years, with the latest figure at $49.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 10.36% year-over-year to $49.1 million; the trailing twelve-month figure through Mar 2026 stood at $49.1 million (down 10.36% YoY), and the FY2025 full-year result was $59.0 million, up 39.05% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $49.1 million, down from $59.0 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $59.0 million in Q4 2025, with the low at $19.6 million in Q3 2023.
• Historically, Total Non-Current Liabilities has averaged $44.1 million across 5 years, with a median of $45.1 million in 2024.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities surged 104.11% — and 2026, when it slipped 10.36%.
• TriSalus Life Sciences' Total Non-Current Liabilities stood at $33.9 million in 2022, then retreated by 2.71% to $33.0 million in 2023, then gained by 28.56% to $42.5 million in 2024, then soared by 39.05% to $59.0 million in 2025, then retreated by 16.85% to $49.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $49.1 million (Q1 2026), $59.0 million (Q4 2025), and $58.2 million (Q3 2025), per Business Quant data.